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Background: Chronic obstructive pulmonary disease (COPD) is an important cause of occupational
mortality in miners exposed to coal mine dust. Although the inﬂammatory mediators involved in COPD
have not been deﬁned, many studies have shown that inﬂammatory mediators such as reactive oxygen
and nitrogen species are involved in orchestrating the complex inﬂammatory process in COPD.
Methods: To investigate the relevance of exhaled biomarkers of oxidative and nitrosative stress in par-
ticipants with COPD, we determined the levels of hydrogen peroxide, malondialdehyde (MDA), and 3-
nitrotyrosine (3-NT) in exhaled breath condensate (EBC) in 90 retired elderly coal miners (53 non-COPD
and 37 COPD participants).
Results: Mean levels of MDA (4.64 nM vs. 6.46 nM, p¼ 0.005) and 3-NT (3.51 nM vs. 5.50 nM, p¼ 0.039) in
EBC were signiﬁcantly higher in participants with COPD. The median level of MDA did show statistical
difference among the COPD severities (p¼ 0.017), and the area under the receiver operating characteristic
curve forMDA (0.67) for the diagnostic discrimination of COPD indicated the biomarker. The optimal cutoff
values were 5.34 nM (64.9% sensitivity and 64.2% speciﬁcity) and 5.58 nM (62.2% sensitivity and 62.3%
speciﬁcity) forMDA and 3-NT, respectively. The results suggest that high levels ofMDA and 3-NT in EBC are
associated with COPD in retired elderly miners.
Conclusion: These results showed that the elevated levels of EBC MDA and EBC 3-NT in individuals with
COPD are biomarkers of oxidative or nitrosative stress.
 2014, Occupational Safety and Health Research Institute. Published by Elsevier. All rights reserved.1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by persistent airﬂow limitation that is usually progressive and
associated with an enhanced chronic inﬂammatory response to
noxious particles or gases in the airways and lungs [1]. Among
occupational lung diseases, themost prevalent diseases are induced
by inhalation of dust, including asbestos, crystalline silica, and coal.
Exposure to silica and coal mine dust may result in pulmonary
scarring in a pattern that mimics idiopathic pulmonary ﬁbrosis, and
in COPD that appears indistinguishable from the obstructive lung
disease caused by exposure to tobacco smoke [2]. Coal workers’
pneumoconiosis and COPD are important causes of occupational
mortality in miners with extensive exposure to coal mine dust [3].nstitute, KoreaWorkers’ Compensat
erms of the Creative Commons At
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l Safety and Health Research InstitThe role of inﬂammatorymediators in the development of COPD
has not been clearly deﬁned, but it is now apparent that many of
them, such as reactive oxygen and nitrogen species, cytokines,
chemokines, and growth factors, are involved in orchestrating the
complex inﬂammatory process in COPD [4]. One of the pathogenic
processes of COPD is oxidative stress, which may be a mechanism
that enhances the inﬂammatory response [5].
Detection of inﬂammatory biomarkers of pulmonary diseases
involves invasive techniques, such as obtaining samples of blood,
bronchoalveolar lavage ﬂuid, and induced sputum. Because inva-
sive sampling procedures may induce an inﬂammatory response,
noninvasive techniques, such as sampling exhaled breath conden-
sate (EBC) and exhaled air, have been developed. Analysis of various
biomarkers in exhaled breath has allowed noninvasive monitoringion andWelfare Service, 87, Guryong-ro, Sangnok-gu, Ansan, Gyeonggi 426-858, Korea.
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Saf Health Work 2014;5:91e9692of inﬂammatory and oxidative stress in the respiratory tract in in-
ﬂammatory lung diseases [6e9]. Malondialdehyde (MDA) has been
widely studied as a product of polyunsaturated fatty acid peroxi-
dation resulting from oxidative stress. Increased MDA levels have
been observed in several biological ﬂuids obtained from patients
with different airway diseases including asthma and COPD [10].
Exhaled nitric oxide (NO) released from lung cells, including in-
ﬂammatory cells, epithelial cells, and endothelial cells in the res-
piratory tract, has been known to be an effective biomarker for
diagnosis and treatment of lung disorders including COPD [11e13].
The main form of NO degradation is the rapid reaction with su-
peroxide anion to form the more reactive product peroxynitrite.
Peroxynitrite reacts with tyrosine to form 3-nitrotyrosine (3-NT)
[14]. Thus, NO and protein-associated NT are considered as char-
acteristic markers of nitrosative stress [15]. There have been rela-
tively few reports analyzing EBC biomarkers in elderly retired coal
miners with COPD.
In this study, we hypothesized that the levels of biomarkers of
oxidative and nitrosative stress in the EBC of patients with COPD
are elevated. To test this hypothesis, we evaluated the hydrogen
peroxide (H2O2), MDA, and 3-NT levels in the EBC.
2. Materials and methods
2.1. Participants
A group of 90 retired male miners were recruited and examined
for pneumoconiosis at Ansan Workers’z Compensation Hospital,
KoreaWorkers’ Compensation andWelfare Service (KCOMWEL). The
data collected included the forced vital capacity (FVC) and the forced
expiratory volume in 1 second (FEV1). Personal information,
including age, bodymass index (BMI), and demographic information
such as job and smoking status were obtained using a structured
questionnaire. Pulmonary function testing was performed in accor-
dance with international guidelines using a Vmax22 spirometer
(SensorMedics, San Diego, CA, USA) [16]. FVC, which is the volume
delivered during an expiration made as forcefully and completely as
possible starting from full inspiration, and FEV1 were measured. A
clinical diagnosis of COPD was considered in participants who
showed an FEV1/FVC ratio< 70% andwithout FEV1 increasing higher
than 200 mL and 12% after b2-bronchodilator inhalation.
Chest radiographs for the diagnosis of pneumoconiosis were
obtained and scored according to the International Labor Ofﬁce
classiﬁcation rules [17] by an experienced panel of physicians from
the Pneumoconiosis ReviewCommittee associatedwith KCOMWEL.
2.2. EBC collection
Collection of EBC was performed in accordance with the
guidelines of the American Thoracic Society [18]. In brief, all par-
ticipants rinsed their mouths with puriﬁed saline prior to collec-
tion. Between 1 mL and 3 mL of EBC was collected during 10
minutes of oral tidal breathing using an EBC collection system
(ECoscreen 2; FILT GmBH, Berlin, Germany). The participants wore
nose clips while collecting the condensate to prevent air from
escaping. The collected EBC samples were immediately stored
at 80C and analysis was performed within 1 month of collection.
2.3. Analysis of biomarkers in EBC
The H2O2 levels in EBC were measured by automated ﬂow in-
jection analysis with ﬂuorescence detection (high-performance
liquid chromatography system; Agilent 1200 Series; Agilent tech-
nologies, Waldbronn, Germany), as previously described [19]. In
brief, 150 mL of EBC samples or standard was added to 15 mL of amixture of 2.5 U/L horseradish peroxidase and 2.5 mM p-hydrox-
yphenylacetic acid. The injection volume was 20 mL and the exci-
tation and emission wavelengths were 285 nm and 400 nm,
respectively.
Analysis of MDA levels in EBC samples was performed by liquid
chromatography-atmospheric pressure chemical ionization-tan-
dem mass spectrometry (LC-APCI-MS/MS, 3200QTRAP, AB SCIEX,
CA, USA; Fig. 1), as previously described [20]. In brief, samples were
derivatized with 2,4-dinitrophenylhydrazine solution (12 mM in
acetonitrile and 2% formic acid) at room temperature for 60 mi-
nutes, after which 20 mL of the derivatized samples was injected
onto the LC-APCI-MS/MS system (3200QTRAP). Chromatography of
derivatives was performed on a C18 reverse-phase column (Triart-
C18; 2.0 mm  100 mm, 3 mm, YMC Co. Ltd, Shimogyo-ku, Kyoto,
Japan) using 20 mM aqueous acetic acid and methanol under
gradient elution condition at a ﬂow rate of 0.2 mL min1. The
gradient program was as follows: from 45% to 98% methanol in 4
minutes, linear gradient, and then hold for 4.5 minutes. The target
ion of derivatives was m/z 235/159 in the positive mode.
A sandwich enzyme immunoassay was used to measure 3-NT
(NWLSS Nitrosine ELISA Kit, NWK-NTR01, Northwest Life Science
Specialties, Vancouver, Canada) levels in accordance with the
manufacturer’s instructions.
2.4. Statistical analyses
Levels of H2O2 and 3-NT in EBC showed a log-normal distribu-
tion. The values were log-transformed for parametric statistical
tests, and the parametric unpaired Student t test and analysis of
variance test were used to determine the magnitudes of between-
group differences. If the sample sizes among the study groups were
also different or the number of cases for each group were incom-
patible for parametric statistical tests, the nonparametric Manne
Whitney U test and KruskaleWallis one-way analysis based on rank
sums were used to determine differences among the study groups.
A multiple regression model was constructed to compare non-
COPD participants with those who had COPD, which was then
adjusted for age, BMI, exposure period, smoking status, and
pneumoconiosis. Receiver operating characteristic (ROC) curve
analysis was used to assess the potential of each exhaled biomarker
for the discrimination of COPD. Statistical cutoff values were
calculated by minimizing the distance between the point with
speciﬁcity ¼ 1 and sensitivity ¼ 1 and various points on the ROC
curve. For ROC analysis, an area under the curve (AUC) of 1.0 in-
dicates perfect discrimination, whereas an area of 0.5 indicates that
the test discriminates no better than chance. The relationship be-
tween biomarkers and effective variables was evaluated using
stepwise multiple regression analysis. Values of p < 0.05 were
considered statistically signiﬁcant. All statistical evaluations were
performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).
2.5. Ethics statement
The study protocol was approved by our institute’s Research
Ethics Committee (Approval number 2010-03-04). All participants
signed an informed consent form that conformed to the recom-
mendations of the committee.
3. Results
3.1. General characteristics
The general characteristics of the study participants are shown
in Table 1. Of the 90 study participants, 37 were diagnosed with
COPD, whereas the remaining 53 were classiﬁed as the non-COPD
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Fig. 1. Chromatogram of malondialdehyde (MDA) using liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry. EBC, exhaled breath
condensate.
Table 1
General characteristics of the study participants
Non-COPD (n ¼ 53) COPD* (n ¼ 37) p
Age (y) 62.1  8.0 65.1  7.4 0.072y
BMI (kg/m2) 23.0  3.2 23.4  2.4 0.338y
Exposure period (y) 18.7  5.9 16.6  8.2 0.645y
%FVC predicted 94.7  15.4 94.4  11.6 0.904y
%FEV1 predicted 104.6  18.4 85.4  13.4 <0.001y
%FEV1/FVC ratio 77.9  4.6 62.7  7.4 <0.001y
Smoking, N (%)
Never 8 (15.1) 2 (5.4) 0.343z
Past 27 (50.9) 20 (54.1)
Current 18 (34.0) 15 (40.5)
Cumulative smoking
(pack-years)
17.1  15.6 20.5  13.2 0.291y
Pneumoconiosis, N (%)
No 29 (54.7) 8 (21.6) 0.001z
Yes 24 (45.3) 29 (78.4)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 second; FVC, forced vital capacity.
* Individuals with COPD are those with FEV1/FVC ratio < 70% and without FEV1
increasing higher than 200 mL and 12% after b2-bronchodilator inhalation.
y Calculated by t test, arithmetic mean  arithmetic standard deviation.
z Calculated by c2 test.
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sure period, %FVC predicted, and smoking status were similar in
both study groups, whereas %FEV1 predicted and chest radiographs
of pneumoconiosis were different.3.2. Exhaled biomarker concentrations
Exhaled biomarker concentrations in the COPD and non-COPD
groups are shown in Tables 2 and 3. The mean EBC MDA level was
signiﬁcantly elevated in participants with COPD (4.64 nM vs.
6.46 nM, p ¼ 0.005). This effect held true in the adjusted multiple
regression model (p ¼ 0.002 for all comparisons). The mean EBC 3-
NT level was also signiﬁcantly higher in participants with COPD
(3.51 nM vs. 5.50 nM, p ¼ 0.039), and the signiﬁcance did show in
the adjustedmultiple regressionmodel (p¼ 0.042). We did not ﬁnd
statistically signiﬁcant intergroup differences in the mean value of
EBC H2O2 levels. The median level of EBC MDA tends to increase
with regard to COPD severities, non-COPD (4.70 nM), mild COPD
(5.93 nM), and moderate COPD (7.20 nM), and there was statistical
signiﬁcance related to COPD severities (p ¼ 0.017; Table 4). The
median level of EBC 3-NT tends to increase with regard to COPD
severities, non-COPD (3.31 nM), mild COPD (6.81 nM), and
Table 2
Associations between mean levels of EBC biomarkers related to general characteristics
N H2O2 (mM) MDA (nM) 3-NT (nM)
Mean (SD)* p Mean (SD)y p Mean (SD)* p
Age (y)z <59 30 0.37 (1.97) 0.654 4.97 (3.29) 0.654 3.76 (2.28) 0.697
60e69 44 0.38 (2.29) 5.56 (2.70) 4.62 (2.76)
>70 16 0.45 (1.82) 5.72 (3.83) 4.11 (2.64)
BMI (kg/m2)x <25 62 0.40 (2.26) 0.340 5.59 (3.01) 0.358 4.66 (2.71) 0.173
25 28 0.34 (1.70) 4.95 (3.30) 3.40 (2.84)
Exposure period (y)z >9 15 0.37 (1.79) 0.320 4.10 (2.36) 0.017 4.88 (2.93) 0.797
10e19 47 0.43 (2.16) 6.26 (3.32) 3.99 (2.72)
>20 28 0.33 (2.12) 4.63 (2.68) 4.31 (2.83)
Smokingz Never 10 0.39 (1.95) 0.927 6.06 (2.16) 0.273 4.57 (3.16) 0.617
Past 47 0.37 (1.74) 4.89 (2.74) 4.58 (2.69)
Current 33 0.40 (2.65) 5.91 (3.72) 3.67 (2.80)
Cumulative smoking 0 10 0.39 (1.95) 0.980 6.06 (2.16) 0.339 4.57 (3.16) 0.820
(pack-y)z 1e9 18 0.38 (1.69) 5.58 (3.84) 3.47 (2.99)
10e19 23 0.40 (1.98) 6.07 (3.36) 4.19 (3.24)
>20 39 0.37 (2.41) 4.73 (2.73) 4.55 (2.36)
COPDx No 53 0.38 (1.96) 0.842 4.64 (2.66) 0.005 3.51 (2.91) 0.039
Yes 37 0.39 (2.30) 6.46 (3.40) 5.50 (2.41)
Pneumoconiosis No 37 0.38 (1.75) 0.828 5.35 (2.98) 0.912 4.15 (2.81) 0.893
Yes 53 0.39 (2.33) 5.42 (3.21) 4.28 (2.75)
3-NT, 3-nitrotyrosine; BMI, body mass index; COPD, chronic obstructive pulmonary disease; EBC, exhaled breath condensate; MDA, malondialdehyde; SD, standard deviation.
* Geometric mean (geometric standard deviation).
y Arithmetic mean (standard deviation).
z Calculated by analysis of variance test.
x Calculated by t test.
Saf Health Work 2014;5:91e9694moderate COPD (7.71 nM); however, the median level did not show
any statistical signiﬁcance related to COPD severities.
The result of ROC curve of MDA and 3-NT in EBC for the diag-
nostic discrimination of COPD is shown in Fig. 2. The area under the
ROC curve for EBC MDA and 3-NT were 0.67 [95% conﬁdence in-
terval (CI): 0.56e0.79, p ¼ 0.004] and 0.62 (95% CI: 0.50e0.74,
p ¼ 0.058), respectively. The optimal cutoff values were 5.34 nM
(64.9% sensitivity and 64.2% speciﬁcity) and 5.58 nM (62.2%
sensitivity and 62.3% speciﬁcity), respectively.4. Discussion
The toxicity of crystalline silica and coal dust is mediated by the
activation of macrophages and induction of lung inﬂammation.
Many researchers expressed concern over the induction of crucial
mediators of pulmonary disorders by these mineral dusts [2].
Inhaled dusts or other transitional metals, including iron, copper,
and vanadium, are known to induce the generation of reactive
oxygen species (ROS) from activated phagocytes in the lung [21e
23]. Pneumoconiosis is the most prevalent lung disease showing a
decrease of pulmonary function. Exposure to coal mine dust canTable 3
Mean concentration of biomarkers in exhaled breath condensate related to COPD
Non-COPD
(n ¼ 53)
COPD
(n ¼ 37)
p
Univariate* Multivariatey
H2O2 (mM)z 0.38 (1.96) 0.39 (2.30) 0.842 0.425
MDA (nM)x 4.64 (2.66) 6.46 (3.40) 0.005 0.002
3-NT (nM)z 3.51 (2.91) 5.50 (2.41) 0.039 0.042
3-NT, 3-nitrotyrosine; COPD, chronic obstructive pulmonary disease; MDA,
malondialdehyde.
* Calculated by t test.
y Calculated using a multiple regression model to adjust for age, body mass index,
exposure period, smoking status (no/yes), cumulative smoking, pneumoconiosis (no/
yes), and each biomarkers in exhaled breath condensate (log H2O2, MDA, log 3-NT).
z Geometric mean (geometric standard deviation).
x Arithmetic mean (standard deviation).cause both pneumoconiosis and chronic airﬂow limitation, espe-
cially small airway dysfunction [2,24].
Similar to the use of biomarkers found in blood and urine,
analysis of biomarkers in breath samples using noninvasive tech-
niques such as EBC collection could be useful for detection of res-
piratory diseases as well as systemic diseases. EBC has been studied
in a variety of diseases, including asthma, COPD, cystic ﬁbrosis,
allergic rhinitis, and lung cancer [6]. EBC can be collected by cooling
or freezing exhaled air and thereby condensing vapor and aero-
solized droplets emerging with the breath [25]. The composition of
EBC is thought to closely reﬂect the composition of the alveolar
lining ﬂuid because of the substantial surface area from which the
generation of aerosols may occur [26].
Oxidative stress is an important feature of COPD, and there is
increasing evidence that it is involved in the pathophysiology of
COPD. Oxidative stress may be induced by cigarette smoke that
activates inﬂammatory cells, such as macrophages and neutrophils
[4]. In previous studies, the levels of EBC H2O2, a type of ROS, were
increased in patients with COPD, particularly during exacerbations
[27,28]. However, in this study, there were no signiﬁcant correla-
tions between EBC H2O2 levels and COPD. This discrepancy might
be due to the fact that previous reports compared the generalTable 4
Median levels of biomarkers in exhaled breath condensate related to COPD
severities*
GOLD 0 (n ¼ 53) GOLD I (n ¼ 27) GOLD II (n ¼ 10) py
H2O2 (mM) 0.36 (44.2) 0.42 (47.3) 0.39 (47.7) 0.844
MDA (nM) 4.70 (39.2) 5.93 (52.6) 7.20 (59.9) 0.017
3-NT (nM) 3.31 (41.1) 6.81 (50.5) 7.77 (55.1) 0.146
3-NT, 3-nitrotyrosine; COPD, chronic obstructive pulmonary disease; FEV1,
forced expiratory volume in 1 second; FVC, forced vital capacity; MDA,
malondialdehyde.
* COPD severity was categorized based on global initiative for chronic obstructive
lung disease (GOLD) classiﬁcation as follows: GOLD 0: FEV1/FVC ratio  70% and
FEV1  80% predicted. GOLD I (mild): FEV1/FVC ratio < 70% and FEV1  80% pre-
dicted. GOLD II (moderate): FEV1/FVC ratio < 70% and 50%  FEV1 < 80% predicted.
y Calculated by KruskaleWallis H test, median (mean rank).
Fig. 2. Receiver operating characteristics (ROC) curve of malondialdehyde (MDA) and
3-nitrotyrosine (3-NT) in exhaled breath condensate (EBC) for the diagnostic
discrimination of chronic obstructive pulmonary disease. Area under the curve of the
ROC curve of EBC MDA and 3-NT were 0.67 [95% conﬁdence interval (CI): 0.56e0.79;
p ¼ 0.004] and 0.62 (95% CI: 0.50e0.74, p ¼ 0.058), respectively. The optimal cutoff
values were 5.34 nM (64.9% sensitivity and 64.2% speciﬁcity) and 5.58 nM (62.2%
sensitivity and 62.3% speciﬁcity), respectively.
J.S. Lee et al / MDA and 3-NT in COPD 95population and patients with respiratory disease, whereas our
study was conducted in retired elderly coal miners. van Beurden
et al [29] reported that the concentrations of EBC H2O2 reduced
after inhaled corticosteroid therapy in patients with COPD. There-
fore, future studies should aim to ascertain the correlation between
EBC H2O2 levels and COPD adjusted for age and pharmacological
therapy.
There is considerable evidence that oxidative stress is increased
in patients with COPD, and ROS contributes to the pathophysiology
of this disease entity [28,30]. Oxidative stress leads to the direct
oxidation of arachidonic acid [31]. MDA is generated by arachidonic
and docosahexenoic acid resulting from lipid peroxidation [32].
Among the mechanisms of ROS damage, lipid peroxidation is
probably the most extensively investigated process. Oxidation of
polyunsaturated fatty acid results in the formation of unstable lipid
hydroperoxides and secondary carbonyl compounds such as alde-
hydes. Among these, EBC MDA has been most frequently demon-
strated as a biomarker of lipid peroxidation in patients with several
respiratory diseases, such as COPD [32] and asthma [33]. In this
study, EBC MDA concentration was higher in the COPD group,
conﬁrming similar observations in previous reports [28,34]. Our
results show that the EBC MDA concentration in the COPD group
was higher than that in the non-COPD group and tends to increase
in relation to COPD severities. Applying ROC curve analyses, AUC for
EBC MDA value (0.67; p ¼ 0.004) for the identiﬁcation of COPD
indicated the reasonable potential of EBC MDA as biomarkers. The
cutoff value of EBC MDA was 5.34 nM (sensitivity 64.9; speciﬁcity
64.2%). These results suggest that the level of EBC MDAmight serve
as a biomarker for oxidative stress in COPD.
In patients with COPD, NO is generated by an enzyme called
inducible NO synthase that is expressed in macrophages and the
lung parenchyma, particularly in patients with severe stage of
COPD [4]. NO can react in vitro with the superoxide ion to produce
peroxynitrite, a potent oxidant with a short half-life. Peroxynitrite
is considered to be the major reactive form of NO in vivo, especially
under conditions of inﬂammation in which the production of ox-
ygen-free radicals is prominent [35]. Peroxynitrite reacts with free
or protein-bound tyrosine residues producing 3-NT, a stable endproduct [14]. In this study, the mean EBC 3-NT level was signiﬁ-
cantly higher in participants with COPD (3.51 nM vs. 5.50 nM,
p ¼ 0.039), and this effect held true in the adjusted multiple
regression model (p ¼ 0.002 for all comparisons). The median level
of EBC 3-NT tends to increase in relation to COPD severities, non-
COPD (3.31 nM), mild COPD (6.81 nM), and moderate COPD
(7.71 nM); however, the median level did not show any statistical
signiﬁcance related to COPD severities. Applying ROC curve ana-
lyses, AUC for the EBC 3-NT value for the identiﬁcation of COPDwas
0.62 (p ¼ 0.058). Therefore, future studies should aim to ascertain
the correlation between EBC 3-NT levels and COPD from a large
number of study participants.
Toxicities of crystalline silica and coal dust are based on the
activation of macrophages and lung inﬂammation. Many re-
searchers have shown concern with regard to crucial mediators of
the pulmonary disorder resulting from these mineral dusts [2].
Inhaled dusts or other transitional metals, including iron, copper,
and vanadium have been known to induce ROS generated from
activated phagocytes in the lung [22]. Exposure to coal mine dust
may result in pneumoconiosis and COPD, including emphysema
and chronic bronchitis that appears indistinguishable from
obstructive lung disease. Coal mine and silica dust may therefore
result in restrictive, obstructive, ormixed patterns of impairment in
pulmonary function testing [36]. Increased ROS levels were re-
ported in several biological conditions, including smoking [5],
pneumoconiosis [2], asthma [33], and COPD. In this study, themean
EBCMDA level was signiﬁcantly elevated in participants with COPD
(p ¼ 0.005) and this effect held true in the adjusted multiple
regression model to adjust for age, BMI, exposure period, smoking
status (no/yes), cumulative smoking, pneumoconiosis (no/yes), and
each biomarker in EBC (p ¼ 0.002). For excluding asthma, we
considered data only from participants who showed an FEV1/FVC
ratio < 70% and without FEV1 increasing higher than 200 mL and
12% after b2-bronchodilator inhalation.
The study has several limitations. One is that 90 participants (53
non-COPD and 37 COPD participants) were insufﬁcient to draw
conclusions about the effects on COPD. Another limitation is with
regard to the lack of data on female participants. In this study, no
signiﬁcant correlations were observed between the incidence of
pneumoconiosis and EBC H2O2, MDA, and 3-NT levels. The expla-
nation for these results may be that the radiological ﬁndings for
pneumoconiosis are inﬂammation or ﬁbrosis in the lung, whereas
the analyzed biomarkers result from the current oxidative stress
response to inﬂammation or exposure to hazardous materials.
In summary, this study showed that the elevated levels of EBC
MDA and EBC 3-NT of COPD patients are biomarkers of oxidative or
nitrosative stress in retired elderly coal miners. Further longitudinal
follow-up studies are needed to investigate the potential of using
exhaled mediators as biomarkers of COPD exacerbation or pro-
gressive pneumoconiosis.
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